Digestery
Longevity supplements › Metformin and Aging › Studies

Population study: followed a group

Study of 4851 Swedes with esophageal cancer: metformin use went with lower death risk

Wang and colleagues · JNCI cancer spectrum · 2023

Original title: Diabetes, metformin use, and survival in esophageal cancer: a population-based cohort study.

Under review. A person has not yet checked this summary against the paper. It is written from the PubMed abstract. Until a person checks it, search engines are asked not to list this page.

What the study found

Points to benefit

Compared with diabetic cancer patients not on metformin, metformin users had lower all-cause mortality (HR = 0.86, 95% CI = 0.75 to 1.00). Higher metformin doses went with lower death risk (Ptrend = .04).

The study at a glance

Type of study
Population study: followed a group
Who or what was studied
4,851 people · Swedish people with esophageal cancer, with and without diabetes
What was tested
Diabetes status and metformin use vs death over follow-up
What it measured
The question itself: aging, frailty and death in people without diabetes
Who has a stake
No stake declared
No competing interests declared.
Journal
JNCI cancer spectrum, 2023
Source
PubMed record 37314979. This page is based on the abstract only.

How much this study counts

  • –Shows a link, not a cause: people chose their own habits, and other differences between them may explain the result.
  • ✓Followed people over time, so habits were recorded before the outcome happened.
  • •4,851 people.
  • ✓Measured the question itself: aging, frailty and death in people without diabetes.
  • ✓No competing interests declared.
  • •Summarized from the PubMed abstract only. The full paper may hold details the abstract leaves out.

✓ Strength– Limit• Note

These points come from fixed rules about the type of study, its size and length, what it measured, and who has a stake. Every study on Digestery gets the same rules.

Where this study sits

Each dot is one on-topic paper on this question. Steps near the top answer the question more directly.

↑ Stronger evidence

  1. Trials in people: aging and age-related disease

    1

    1 benefit

  2. Trials in people: other measures

    3

    2 no difference, 1 harm

  3. Trials in people: lab tests or safety

    6

    2 benefit, 2 mixed, 2 no difference

  4. Population studies

    8

    6 benefit, 2 no difference

    ↑ This study is the ringed dot

  5. Blood levels and genes

    0

    None among the papers we read.

  6. Animals

    3

    2 benefit, 1 harm

↓ Weaker evidence

  • Points to benefit
  • Mixed
  • No difference
  • No direction
  • Points to harm

How it fits with the other research

The short answer to “Does metformin slow aging in people without diabetes?”

Not shown in people without diabetes.

Confidence: low. Based on 26 on-topic papers.

Read the full answer

Of the other 7 papers on the same step: 5 benefit, 2 no difference. This one found benefit. It agrees with most of them.

Other papers on the same step

See all 26 studies on this question

How this page was made

Label

First read of the abstract
Claude Sonnet
Independent second read
Claude Haiku
Differences settled
The reviewer corrected 1 field after reading the abstract. Claude Opus 5.5.
Headline
Claude Sonnet, from the checked study record. A script checked its numbers and wording.
Numbers
Checked against the abstract by a script
“How much this study counts”
Fixed rules, the same for every study
Source check by a person
Not yet. Required before search engines may list this page.

Spot an error? Email a flag with a link to your source, or use the form on the question page.